Research Article

Flemingia philippinensis Flavonoids Relieve Bone Erosion and Inflammatory Mediators in CIA Mice by Downregulating NF-κB and MAPK Pathways

Guangchen Sun, Congcong Xing, Luting Zeng, Yijie Huang, Xin Sun, and Yingqin Liu

1Pharmacy College, Guilin Medical University, Guilin, Guangxi, China
2Medical College, Xiamen University, Xiamen, Fujian, China
3Biotechnology College, Guilin Medical University, Guilin, Guangxi, China

Correspondence should be addressed to Yingqin Liu; liuyq@glmc.edu.cn

Guangchen Sun and Congcong Xing contributed equally to this work.

Received 25 July 2018; Revised 29 November 2018; Accepted 30 December 2018; Published 17 February 2019

Academic Editor: Carlos Rossa

Copyright © 2019 Guangchen Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The dry root of Flemingia philippinensis has been widely used in the treatment of rheumatism, arthropathy, and osteoporosis in traditional Chinese medicine; the therapeutic effects of Flemingia philippinensis are associated with antiarthritis in traditional Chinese medicine theory. This study was undertaken to investigate the mechanism of bone erosion protection and anti-inflammatory effect of Flemingia philippinensis flavonoids (FPF) in collagen-induced arthritis (CIA) in mice. Methods. Flavonoids were extracted from the dry root of Flemingia philippinensis. Collagen-induced arthritis in C57BL/6 mice was used as a rheumatoid arthritis model, and the mice were orally fed with FPF prior to induction to mimic clinical prophylactic therapy for a total of 39 days. After treatment, histology and immunohistochemistry staining were performed, and the levels of anti-collagen type II (CII) antibody and inflammatory mediators, as well as the key proteins of nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, were detected in the samples taken from ankle joints, plasma, and paws. Results. FPF administration significantly suppressed the paw swelling and arthritic score in CIA mice. FPF reduced inflammation and pannus formation, articular cartilage destruction and osteoclast infiltration, and the expression of MMP-9 and cathepsin K in the ankle joint. FPF inhibited plasma anti-CII antibody levels and the production of inflammatory cytokines and chemokines in CIA paws. FPF treatment suppressed the activation of NF-κB as indicated by downregulating the phosphorylation of NF-κB p65 and mitogen-activated protein kinase (MAPK) pathways, were detected in the samples taken from ankle joints, plasma, and paws. Additionally, FPF significantly inhibited inflammation signaling by suppressing the activation of NF-κB by attributable to an anti-inflammatory effect on CIA by preventing bone destruction, regulating inflammatory mediators, and suppressing NF-κB and MAPK signaling pathways.

1. Introduction

Flemingia philippinensis (Merr. et Rolfe) is a shrubby herb that belongs to a family of Leguminosae; its roots are popularly used to treat rheumatism, arthropathy, leucorrhea, menalgia, menopausal syndrome, chronic nephritis, and osteoporosis in traditional Chinese medicine [1]. Previous studies showed that the roots of Flemingia philippinensis contain a variety of flavonoids, especially prenylated iso-flavones, which showed anti-inflammatory, antiestrogen,
antitumor, cytotoxic, immunosuppressive, and antioxidant activities [1–7]; however, its role on rheumatoid arthritis needs to be further studied.

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial hyperplasia, inflammatory cell infiltration, pannus formation, and cartilage and subchondral bone erosion. Continuous synovium inflammation subsequently results in severe deformity and loss of function. Studies have shown that many cells are involved in the pathogenesis of RA, including monocytes/macrophages, T cells, and B cells. Inflammatory cells infiltrate the synovium and further activate the release of cytokines, chemokines, autoantibodies, and matrix metalloproteinases (MMPs) [8]. Furthermore, a wide range of proinflammatory cytokines including interleukin-1 (IL-1), IL-6, IL-12, or IL-23, tumor necrosis factor-α (TNF-α), and chemokines such as monocyte chemoattractant protein-1 (MCP-1) coordinate with M-CSF/RANK signals to promote osteoclast-mediated bone erosion [9–11]. Of particular note, induction of these inflammatory cytokines is mediated by the signal pathways including nuclear factor-κB (NF-κB), mitogen-activated protein kinases (MAPKs), activating protein-1 (AP-1) and signal transducers, and activators of transcription 3 (STAT3). NF-κB is a key transcriptional regulator that plays a critical role at the onset of inflammation following IκB degradation [12, 13]. Previous studies have shown that NF-κB plays a key role in mouse models of arthritis, and blocking NF-κB has a dramatic effect in preventing the disease [14, 15]. The MAPK signaling pathway including extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK) positively regulates a number of cytokines, chemotactic factors, and other enzymes and is thought to have a key role in the pathogenesis of RA [16, 17]. Therefore, the inhibitors of NF-κB or MAPK may be effective as an antiarthritis agent.

Therefore, this study was conducted to investigate the protective effects of Flemingia philippinensis flavonoids (FPF) on the bone erosion in a CIA mouse model and the expression of cytokines and transcription factors. Our results showed that FPF has therapeutic effects on the CIA disease by regulating NF-κB and the MAPK pathway protein. Furthermore, the results of this study may provide evidence for the future clinical application of FPF in the treatment of RA.

2. Materials and Methods

2.1. Reagents and Antibodies. The Flemingia philippinensis root was purchased from a traditional herb market in Guilin, China, and authenticated by a taxonomist. The voucher specimen was stored in Pharmacy College, Guilin Medical University, Guilin, China. Chicken type collagen (CII) and Complete Freund’s Adjuvant were purchased from Sigma-Aldrich. Antibodies to the following proteins were purchased from Santa Cruz Biotechnology, Santa Cruz, CA: goat anti-mouse IgG2a-HRP (sc-2061), MMP-9 (sc-39389), cathepsin K (sc-48353), MCP-1 (sc-52701), phosphorylated STAT3 (sc-8059), phosphorylated IκBα (sc-8404), and phosphorylated NF-κBp65 (sc-101753); antibodies anti-Mouse IgG1-HRP, phosphorylated JNK1+JNK2+JNK3 (ab124956), phosphorylated p38 MAPK (ab178867), and phosphorylated Jun D+c-Jun (ab208035) were purchased from Abcam; phosphorylated ERK1/2 antibody (4370) was from Cell Signaling Technology, GAPDH antibody was from PeproTech Biotechnology, and ELISA kits for TNF-α, IL-10, IL-12/IL-23 p40 (total), and MCP-1 were from eBioscience.

2.2. Total Flavonoid Extraction. Flemingia philippinensis’ dry root was pulverized, and the powder of the Flemingia philippinensis’ dry root was soaked with 70% ethanol for 2 days (solid to liquid ratio 1:14) and refluxed twice (2 h each time), and the mixture was filtered. The final product was evaporated to yield total Flemingia philippinensis flavonoids (FPF 18.38%) and stored at 4°C. The mouse dosage of FPF was transferred from human consumption of Flemingia philippinensis herb. The body surface area normalization method has been prescribed [18, 19].

2.3. Animal. The male C57BL/6 mice were obtained from the Animal Experimental Center of Guilin Medical University (experimental animal production license number: SCXK Gui 2013-0001; experimental animal use permit number: SYXK Gui 2013-0001). The mice were kept on a 12/12 h light/dark cycle under specific pathogen-free conditions; experimental studies were strictly in accordance with Guilin Medical University Animal Ethics Committee guidelines for the rational use of animals.

2.4. Collagen-Induced Arthritis Preparation. Collagen-induced arthritis (CIA) in mice was performed according to the methodology with minor changes [20]. Chicken collagen type II (CII) was dissolved in 0.1 M glacial acetic acid to a final concentration of 2 mg/ml CII, and the solution was emulsified in an equal volume of Complete Freund’s Adjuvant (CFA containing 4 mg/ml mycobacterium tuberculosis) overnight at 4°C. On day 0, the mice in the CIA groups were injected with 100 μl emulsion at the base of the tail by an intradermal route under anesthesia. A booster injection of 50 μl of the same emulsion into the ankle subplantar of both hind limbs was given on day 18. The mice were randomly divided into three groups: normal control group (n = 10) without any treatment, vehicle group (n = 10), and FPF group (n = 9). The mice in the FPF group were intragastrically fed with 40 mg/kg body weight FPF daily from day 7 until the end of the experiment on day 46, while the vehicle group received only water. The thickness of the hind paws was measured using a dial gauge (0.01-10 mm, Peacock Japan), and the clinical score was graded as previously described [21].

2.5. Histopathology and Immunohistochemistry. The mouse ankle joints at day 46 were fixed for 24 h in 4% paraformaldehyde, and the joints were decalcified in 15% EDTA at RT (pH adjusted to 7.2 by addition of ammonium hydroxide) for 4 weeks. Serial paraffin sections (5 μm) were stained for hematoxylin and eosin (H&E) staining and toluidine blue and tartrate-resistant acid phosphatase (TRAP) staining to identify osteoclasts. Histopathologic scoring was performed as previously described in detail [21]. For immunohistochemistry, ankle paraffin sections were dewaxed and rehydrated, and endogenous peroxidase activity was eliminated by incubating sections in 3% H2O2; sections were incubated
in 1% goat serum for 60 min and then incubated with the primary antibody of MMP-9 and cathepsin K overnight at 4°C, followed by horseradish peroxidase (HRP) secondary antibody at room temperature for 1 h, and the signal was developed with DAB chromogen according to the manufacturer’s specifications. The specificity of the staining was confirmed by using matched isotype control antibodies. All sections were counterstained with hematoxylin. Specific expression markers were examined and photographed using a light microscope, and color densities were quantified using the ImageJ software as described elsewhere [22, 23].

2.6. ELISA. Heparinized blood samples were taken from all experimental animals on day 46. Plasma was collected by centrifugating whole blood at 3000 rpm for 10 min and stored at -80°C until use. The levels of anti-CII antibodies in the samples were evaluated by ELISA. In brief, 96 wells were coated overnight at 4°C with 5 μg/ml phosphate solution of chicken CII. The plates were then washed and blocked using 1% bovine serum albumin (BSA). Following the extensive washing, the plasma samples in serial dilutions were added to the plates and incubated overnight at 4°C or 1 h at 37°C. The plates were then washed and incubated with HRP-conjugated anti-mouse immunoglobulin IgG, IgG1, IgG2a, and IgM (BA1075, Boster, China) antibodies. After extensive washing, binding of anti-CII antibodies was revealed by 3,3′,5,5′-tetramethylbenzidine (TMB), and wave-length absorbance was detected under 450 nm. The mouse paws were lysed with Radio Immunoprecipitation Assay (RIPA, 50 mM Tris, 150 mM NaCl, 1% NP-40, and 0.5% sodium deoxycholate) buffer; the extracts were sonicated for 30 s and centrifuged at 20,000 × g for 15 min. The supernatant was collected for measuring the levels of TNF-α, IL-10, IL-12/IL-23 p40 (total), and MCP-1 according to the manufacturer’s instruction.

2.7. Western Blot Analysis. On day 46, the mouse paws and the splenic tissue were homogenized with ice-cold RIPA buffer containing phosphatase inhibitor and protease inhibitor cocktail (S8820, Sigma-Aldrich Shanghai, China), then sonicated 30 s at 4°C, and centrifugated at 12000 rpm for 30 min; the protein concentration in the supernatant was determined by the Bradford method. The protein extracts were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes (PVDF). After being blocked with 5% (ω/ν) BSA for 2 h, the membranes were immuno-blocked with primary antibodies including MMP-9, cathepsin K, MCP-1, phosphorylated (p-) IκBα, p-NF-kBp65, p-ERK1/2, p-JNK1+JNK2+JNK3, p-p38, p-Jun D+c-Jun, p-STAT3, and GAPDH on a shaker overnight at 4°C. The membranes were then washed and incubated for 1 h with the secondary antibody. The antibody labelling of the protein bands was detected by the enhanced chemiluminescence (ECL) detection system. The gray values measured with the Image Lab software were normalized against GAPDH.

2.8. Statistical Analysis. The statistical analysis of the biological data was performed using the SPSS 18.0 software. One-way ANOVA with Student’s t-test was performed to test the significant differences. P < 0.05 was considered statistically significant.

3. Results

3.1. FPF Suppressed CIA. The induction of collagen-induced arthritis is outlined as in Figure 1(a). The effect of FPF on disease progression in CIA mice was investigated by assessing the development of inflammation. The paw thickness was measured along the experiment, and the clinical disease activity was scored at the end of the experiment. The mice in the control group did not develop paw swelling. The disease activity in vehicle-treated mice with CIA first appeared after subplantar injection on day 18, and the severity of the disease increased gradually in CIA mice. On the 46th day of CII injection, the paw swelling of the vehicle-treated mice increased (5.18 ± 0.36 mm), but the paw swelling was reduced to 4.62 ± 0.41 mm when the mice were given 40 mg/kg FPF (Figure 1(b)). Figure 1(c) shows typical swelling of the paws of the mouse groups: normal control mice, collagen-induced control mice, and FPF-treated mice, 46 h after CIA injection. The photographs clearly show that the paw of the mouse treated with FPF is less swollen than CIA-induced vehicle-treated mouse’s paw. On day 46, the clinical score of the paws in the vehicle-treated CIA mice reached 2.69 ± 0.55 but was significantly reduced by 2.20 ± 0.17 in the FPF-treated mice (Figure 1(d)).

3.2. FPF Attenuated the Histological Parameters of CIA Mice. Histology and immunohistochemistry are shown in Figure 2. H&E staining revealed that the FPF-fed group showed limited inflammatory cell infiltration, cartilage erosion, and tissue and pannus formation during CIA joint formation compared with the vehicle group (Figure 2(a), A, B, and C). We qualitatively determined the amount of cartilage proteoglycan by toluidine blue staining, which showed a decreased proteoglycan in the joint and an incomplete staining of the joint in the vehicle group, meaning serious damage occurred in the cartilage. However, a relatively normal proteoglycan with a complete cartilage following FPF treatment implies that FPF can protect the proteoglycan against CIA in mice (Figure 2(b), D). TRAP staining showed that the cartilage was mostly damaged and pannus was formed in the vehicle group, a large number of osteoclasts infiltrated around the bone marrow cavity and pannus, and the injured cartilage and growth plates in the vehicle group had osteoclast distribution. However, these changes were attenuated in the FPF group, indicating that FPF can reduce osteoclast invasion and bone destruction as well as pannus formation (Figures 2(c), E). To clarify whether the cellular components of the inflamed tissue are affected by FPF treatment, the expression of cell-specific markers of the protease inhibitor was quantified by immunohistochemistry. The results suggested that the expressions of MMP-9 and cathepsin K in both the vehicle group and the FPF group were increased compared with those in the control group, but the expressions of both factors in the FPF group were significantly lower than those in the vehicle group, as demonstrated by optical density determination (Figures 2(d) and 2(e)).
Figure 1: Antiarthritic effect of FPF on arthritis edema and soreness in mice with collagen-induced arthritis. C57BL/6 mice with CIA were treated with 40 mg/kg FPF daily from day 7 to day 46. A schematic diagram of CIA model establishment (a), hind paw thickness (b), representative photographs of the hind paws of CIA mice on day 46 (c), and clinical score on day 46 (d) were shown. Values are the mean \( 7-8 \pm \text{SEM} \) of two independent experiments by one-way analysis of variance (ANOVA). * \( P < 0.05 \) and ** \( P < 0.01 \) compared with the vehicle group with CIA.
3.3. FPF Regulated Anti-CII Antibody Levels in Plasma of CIA Mice. We next examined whether FPF treatment could modulate humoral immune responses by assessing antibody production in CIA mice. The anti-type II collagen production of the vehicle-treated group (data not shown), indicating that FPF treatment enhanced antibody production in CIA mice. The anti-type II collagen production of the vehicle-treated group was determined with di-fluorometric analysis (Figure 3), and the spleen level of IgG1 and IgG2a was significantly reduced when compared with those of the vehicle-treated group (data not shown), indicating that FPF treatment efficiently attenuated the humoral immune response.

3.4. FPF Regulated Inflammatory Mediators in CIA Mice. To investigate the effect of FPF on inflammatory mediators for its therapeutic efficiency, the expressions of proinflammatory cytokine (TNF-α), anti-inflammatory cytokine (IL-10), and chemokine (MCP-1) were detected by ELISA in mouse paws. The results showed that FPF significantly inhibited TNF-α and MCP-1 and significantly upregulated IL-10 expression. In addition, FPF treatment also significantly inhibited IL-12/IL-23 total p40 expression levels (Figure 4).

3.5. MAPKs, NF-κB, and STAT3 Pathways Were Involved in Mediating the Effects of FPF on Reducing Inflammation in CIA Mice. Bone and cartilage degradation caused by pannus is associated with increased activity of proteolytic enzymes, including MMPs and cathepsin K. The effects of FPF on the expressions of the two proteolytic enzymes in CIA mice were determined. The results suggested that the expression of MMP-9 and cathepsin K were significantly inhibited by the treatment of FPF as demonstrated by immunohistochemistry and western blot, respectively (Figures 2(d), 2(e), and 5). In view of the above observations, we further investigated the molecular mechanisms of FPF in CIA mice. NF-κB is an important transcription factor to control the synthesis of a variety of inflammatory cytokines such as TNF-α, IL-6, and IL-1, and NF-κB activation requires the phosphorylation of NF-κB [12, 13]. The expression of NF-κB signaling pathway was detected by western blot. FPF also alleviated the expression of MCP-1 in the spleen was detected by western blot. FPF also alleviated the expression of MCP-1 in the spleen (Figure 7). These results clearly demonstrated that FPF inhibited the activation of NF-κB and MAPKs to mediate the production of proinflammatory factors.

4. Discussion

Currently, bisphosphonates are the preferred drug for the pharmacological treatment of bone resorption; in contrast, anti-inflammatory ability has disappeared as seen by using the liposomal chlorophosphonate treatment [26]. The most effective anti-inflammatory therapies so far do not alleviate bone loss and joint damage in RA patients [27, 28]. Glucocorticoids used for RA treatment may cause the adverse reactions with bone loss and fracture for long-term use [29]. Natural products, including natural polyphenolic flavonoids, may be beneficial in the development of new drugs for the treatment of autoimmune diseases including RA, due to the lower adverse reactions [30]. The root of Flemingia philippinensis has been traditionally used for treating rheumatism, arthropathy, and chronic nephritis. Studies reported that the extract of the root of Flemingia philippinensis exhibited antioxidative, anti-inflammatory, estrogenic, and antiestrogenic activities. The prenylated flavonoids in this plant acted as bioactive estrogen [1, 31]. Flavonoid compounds in the root of Flemingia philippinensis showed a strong inhibitory activity on lymphocyte proliferation and the low cytotoxicity on splenic lymphocytes stimulated with concanavalin A or lipopolysaccharide, respectively [4]. However, the effects of this plant or its flavonoids on arthritis are poorly investigated. In the present study, our aim was to explore whether FPF acts as a modulator of inflammation and bone destruction in vivo. For this purpose, we for the first time demonstrated the potential therapeutic action of FPF in an experimental model of rheumatoid arthritis, mimicking the clinical situation of prophylactic treatment for RA. FPF had significant protective effects against cartilage erosion and bone destruction in the affected ankle joint, and its protective effect was associated with the downregulation of TNF-α and MCP-1, the upregulation of IL-10 in the joints of experimental arthritis animals, and the suppression of MAPK and NF-κB activation in CIA.

The CIA model was characterized by the formation of synovial inflammation, massive bone erosion, and cartilage destruction, ultimately leading to complete loss of the joint architecture. In this study, representative markers for 3 main issues, i.e., synovial inflammation, cartilage erosion, and bone destruction (seen on histology), were attenuated, unraveling the interesting features of FPF in CIA treatment. Proinflammatory factors, such as cytokines TNF-α, IL-12, and IL-23 and chemokine MCP-1, play a crucial role in the pathology of synovitis and progressive joint destruction in RA [8, 9, 32–34]. IL-10 is a cytokine with potent anti-inflammatory properties, and it seems to play a dual role in RA by simultaneously suppressing humoral autoimmune response and the activation of STAT3 in CIA mice (Figure 7). Based on the finding that FPF played a role in the regulation of inflammatory mediators in the CIA paws (Figure 3), the expression of MCP-1 in the spleen was detected by western blot. FPF also alleviated the expression of MCP-1 in the spleen (Figure 7). These results clearly demonstrated that FPF inhibited the activation of NF-κB and MAPKs to mediate the production of proinflammatory factors.
In this study, FPF treatment significantly reduced the levels of TNF-α, MCP-1, and p40 subunit of IL-12 and IL-23 in CIA mice and increased the expression of IL-10. It is also well known that an imbalance between pro- and anti-inflammatory cytokine activities is implicated in the induction of autoimmunity, chronic inflammation, and thus joint damage. Proinflammatory cytokines such as TNF-α activate the NF-κB pathway, leading to the production of MMPs that in turn mediate tissue destruction [8]. In contrast, anti-inflammatory cytokines...
such as IL-4 and IL-10 suppress joint damage in RA [36]. The current evidence suggested that FPF shifted the cytokine balance to Th2 cytokines that are beneficial for protecting joint destruction, although FPF treatment attenuated the increase in the levels of both Th1- and Th2-type antibodies IgG2a and IgM against CII. Bar plot ± SEM represent plasma concentrations. *$P < 0.05$ compared with the vehicle group by Student’s $t$-test.

Figure 3: Effect of prophylactic administration of FPF on antibody response to CII in CIA mice. Starting at day 7 after the CII challenge, gavage was performed daily with water and 40 mg/kg FPF until day 46 on the mice. The mice were euthanized, and their plasma was collected for measurement of IgG, IgG1, IgG2a, and IgM against CII. Bar plot ± SEM represent plasma concentrations. *$P < 0.05$ compared with the vehicle group by Student’s $t$-test.

Figure 4: Effect of FPF on proinflammatory and anti-inflammatory mediators in paw tissue. Mice with CIA were untreated or treated with 40 mg/kg FPF daily. On day 46, mice were euthanized, and the cytokines were quantified in paw homogenates by ELISA; the results show the mean of one experiment (seven to eight replicates) ± S.D. *$P < 0.05$; **$P < 0.01$ compared with the vehicle group using Student’s $t$-test.

such as IL-4 and IL-10 suppress joint damage in RA [36]. The current evidence suggested that FPF shifted the cytokine balance to Th2 cytokines that are beneficial for protecting joint destruction, although FPF treatment attenuated the increase in the levels of both Th1- and Th2-type antibodies IgG2a and IgM in CIA mice.

It is well established that NF-$\kappa$B signaling has been implicated in the progress and development of RA by regulating the transcription of proinflammatory cytokine-, chemokine-, and osteoclastogenesis-related genes including cathepsin K and MMP-9. The products of these genes synergistically enhanced the inflammatory response, which in turn leads to further activation of NF-$\kappa$B. In fact, persistent NF-$\kappa$B activation has been found in both animal models and RA patients [14, 15]. Thus, it is clear that NF-$\kappa$B is an important target molecule for RA therapy. In this study, we found that phosphorylation of p65 was triggered in the paw tissue of CIA mice and that this phosphorylation was suppressed by prophylactic doses of FPF, as demonstrated by the results of western blot for p-p65 and both...
immunocytochemistry and western blot for cathepsin K and MMP-9.

The transcriptional activity of NF-κB can be further modulated in the nucleus by three MAPK pathways, including p38, ERK, and JNK. MAPK promotes the production of several cytokines such as TNF-α, IL-6, IL-12, and IL-23, pan-nus formation, and cartilage degradation [37–40]. JNK, ERK, and p38 are constitutively expressed in the RA synovial tissue [17, 41] and are liable to be activated in the joint tissue from RA patients [42]. Preclinical experiments with selective inhibitors of p38, ERK, and JNK kinases provide support for their potential targets in human disease [37, 43, 44]. Hence, JNK and p38 inhibition is a potential therapeutic tragedy for the prevention of matrix destruction. Studies have testified that the phosphorylated MAPKs (p38, ERK, and JNK) transfer to the nucleus and initiate the import and accumulation of AP-1 into the nucleus, thereby regulating the target gene expression. An activated JNK or ERK signaling leads to the accumulation of phospho-c-Jun and phospho-Jun D of AP-1 [37, 45]. In this study, FPF treatment reduced the phosphorylation of MAPK signaling pathway, including p38, JNK, and ERK, and further inhibited the AP-1 expression level, suggesting its targeting MAPK signaling pathway. These results suggest that the effects of FPF on the production of inflammatory mediators are likely mediated through the precluding of MAPK pathway in CIA mice.

NF-κB and STAT3 is recognized to be representative transcription factors that play crucial roles in inflammatory signaling. Numerous reports have suggested that both NF-κB and STAT3 collaborate with each other and contribute to inflammation and that this synergistic interaction between the two transcriptional factors may exacerbate inflammatory responses mediated by inflammatory signaling pathways in many diseases, including RA [25]. In this study, we showed that treatment with FPF attenuated the proinflammatory responses, which was accompanied by the simultaneous inhibition of NF-κB and STAT3 in the paw tissues of the CIA mice. Taken together, the anti-RA effects of FPF may be closely related to the simultaneous downregulation of the STAT3 and NF-κB signaling pathways.

**Figure 5:** FPF treatment inhibited bone degradation proteinase expression, and nuclear factor kappa-B (NF-κB) activation in the CIA mouse model. C57BL/6 mice were injected intradermally at the base of the tail with CII on day 0 and then challenged with 50 μg CII subplantar at both hind limbs on day 18. On day 46, paws were dissected and total proteins were extracted (n = 3–4 each group). Expressions of the indicated cathepsin K, MMP-9, phosphorylated (p-) IκBα, and p-p65 in the paw were examined using western blot and quantified by densitometric analyses. All data are mean ± standard error of the mean (SEM) and *P < 0.05 and **P < 0.01 vs. the vehicle group as determined using Student’s t-test.

**Figure 6:** FPF inhibited activation of JNK123, p38-MAPK, and ERK1/2 in the CIA mouse model. C57BL/6 mice were injected intradermally at the base of the tail with CII on day 0 and then challenged with 50 μg CII subplantar at both hind limbs on day 18. On day 46, paws were dissected and total proteins were extracted (n = 3–4 each group); expressions of phosphorylated (p-) ERK, p-p38, and p-JNK in the paws were detected using western blot and quantified by densitometric analyses. All data are mean ± standard error of the mean (SEM) and *P < 0.05 and **P < 0.01 and ***P < 0.001 vs. the vehicle group as determined using Student’s t-test.
We showed here for the first time that oral FPF administration effectively ameliorated arthritis symptoms in a CIA mouse model including joint inflammation, cartilage damage, and bone destruction, concomitant with inhibiting pro-inflammatory mediators and increasing anti-inflammatory factors and inhibition of NF-kB and MAPK pathways effectively in vivo. This makes FPF a new type of antirheumatoid drug for further evaluation. We demonstrated here that FPF is effective in inhibiting mouse CIA and reducing associated inflammation. Further investigations, such as time-course analyses using localized cells, can provide more detailed insights into the direct and indirect antiarthritic effects of FPF, and the active compounds would be identified in the future study.

5. Conclusions

We showed here for the first time that oral FPF administration effectively ameliorated arthritis symptoms in a CIA mouse model including joint inflammation, cartilage damage, and bone destruction, concomitant with inhibiting pro-inflammatory mediators and increasing anti-inflammatory factors and inhibition of NF-kB and MAPK pathways effectively in vivo. This makes FPF a new type of antirheumatoid drug for further evaluation. We demonstrated here that FPF is effective in inhibiting mouse CIA and reducing associated inflammation. Further investigations, such as time-course analyses using localized cells, can provide more detailed insights into the direct and indirect antiarthritic effects of FPF, and the active compounds would be identified in the future study.

Data Availability

All the data supporting the findings were shown within the paper and can be requested from the corresponding author.

Conflicts of Interest

G.S. and Y.L. received a research grant from NSFC and GXNF. The other authors have no competing interests to declare.

Acknowledgments

The authors are thankful for the grants of the National Natural Science Foundation of China (81260462, 81660304, and 81460474; https://isisn.nsfc.gov.cn/egrantweb/) and the Natural Science Foundation of Guangxi Province (2015GXNFAA139104, 2017GXNSFAA198334, and 2018GXNSFADA 138072; http://gxnsf.gxsti.net/stms/login.jsp). The funding bodies were not involved in any aspects of the study. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

[1] E. M. Ahn, N. Nakamura, T. Akao, T. Nishihara, and M. Hattori, “Estrogenic and antiestrogenic activities of the roots of Moghania philippinensis and their constituents,” *Biological & Pharmaceutical Bulletin*, vol. 27, no. 4, pp. 548–553, 2004.

[2] M. Chen, S. Q. Luo, and J. H. Chen, “Studies on the chemical constituents of Flemingia philippinensis,” *Yao Xue Xue Bao*, vol. 26, no. 1, pp. 42–48, 1991.

[3] H. Li, F. Zhai, M. Yang, X. Li, P. Wang, and X. Ma, “A new benzofuran derivative from Flemingia philippinensis Merr. et Rolfe,” *Molecules*, vol. 17, no. 7, pp. 7637–7644, 2012.

[4] L. Li, X. Deng, L. Zhang, P. Shu, and M. Qin, “A new coumaran with immunosuppressive activities from Flemingia philippinensis,” *Fitoterapia*, vol. 82, no. 4, pp. 615–619, 2011.

[5] M. Fu, D. Deng, R. Huang, N. Zhang, Z. Su, and S. X. Qiu, “A new flavonocoumarin from the root of Flemingia philippinensis,” *Natural Product Research*, vol. 27, no. 14, pp. 1237–1241, 2013.

[6] Y. Wang, M. J. Curtis-Long, H. J. Yuk, D. W. Kim, X. F. Tan, and K. H. Park, “Bacterial neuraminidase inhibitory effects of prenylated isoflavones from roots of Flemingia philippinensis,” *Bioorganic & Medicinal Chemistry*, vol. 21, no. 21, pp. 6398–6404, 2013.

[7] F. Sun, Q. Li, and J. Xu, “Chemical composition of roots Flemingia philippinensis and their inhibitory kinetics on aromatase,” *Chemistry & Biodiversity*, vol. 14, no. 1, 2017.

[8] G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” *Nature*, vol. 423, no. 6937, pp. 356–361, 2003.
[9] I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007.
[10] P. P. C. Souza and U. H. Lerner, “The role of cytokines in inflammatory bone loss,” Immunological Investigations, vol. 42, no. 7, pp. 555–622, 2013.
[11] Z. Szekanecz and A. E. Koch, “Successes and failures of chemokine-pathway targeting in rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 12, no. 1, pp. 5–13, 2015.
[12] T. D. Gilmore and F. S. Wolenski, “NF-κB: where did it come from and why?,” Immunological Reviews, vol. 246, no. 1, pp. 14–35, 2012.
[13] J. A. DiDonato, F. Mercurio, and M. Karin, “NF-κB and the link between inflammation and cancer,” Immunological Reviews, vol. 246, no. 1, pp. 379–400, 2012.
[14] A. V. Miagkov, D. V. Kovalenko, C. E. Brown et al., “NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 23, pp. 13859–13864, 1998.
[15] E. Jimi, K. Aoki, H. Saito et al., “Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo,” Nature Medicine, vol. 10, no. 6, pp. 617–624, 2004.
[16] S. E. Sweeney and G. S. Firestein, “Primer: signal transduction in rheumatic disease—a clinician’s guide,” Nature Clinical Practice Rheumatology, vol. 3, no. 11, pp. 651–660, 2004.
[17] G. Schett, J. Zwerina, and G. Firestein, “The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 7, pp. 909–916, 2007.
[18] S. Reagan-Shaw, M. Nihal, and N. Ahmad, “Dose translation from animal to human studies revisited,” The FASEB Journal, vol. 22, no. 3, pp. 659–661, 2008.
[19] K. Wojcikowski and G. Gobe, “Animal studies on medicinal herbs: predictability, dose conversion and potential value,” Phytotherapy Research, vol. 28, no. 1, pp. 22–27, 2013.
[20] C. Bao, Y. Liu, X. Sun, C. Xing, L. Zeng, and G. Sun, “Periplacenta saponin ameliorates CIA via suppressing proinflammatory cytokines and nuclear factor kappa-B pathways,” PLoS One, vol. 12, no. 5, article 0176672, 2017.
[21] J. C. Scatizzi, E. Bickel, J. Hutcheson, G. K. Haines III, and H. Perlman, “Bim deficiency leads to exacerbation and prolongation of joint inflammation in experimental arthritis,” Arthritis & Rheumatism, vol. 54, no. 10, pp. 3182–3193, 2006.
[22] C. C. Saxena, R. Safaya, N. Kawatra Madan, S. A. Khan, and V. K. Iyer, “Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone,” Journal of Clinical Orthopaedics and Trauma, vol. 7, no. 2, pp. 109–114, 2016.
[23] K. Young and H. Morrison, “Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using ImageJ,” Journal of Visualized Experiments, vol. 5, no. 136, 2018.
[24] J. Zwerina, S. Hayer, K. Redlich et al., “Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction,” Arthritis & Rheumatism, vol. 54, no. 2, pp. 463–472, 2006.
[25] P. Kotthoff, A. Heine, S. A. E. Held, and P. Brossart, “Dexamethasone induced inhibition of dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways,” Scientific Reports, vol. 7, no. 1, p. 4522, 2017.
[26] A. Ceponi, E. Waris, J. Mönkönen et al., “Effects of low-dose, noncytotoxic, intraarticular liposomal cladronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits,” Arthritis & Rheumatism, vol. 44, no. 8, pp. 1908–1916, 2001.
[27] D. A. Eekman, M. Vis, I. E. M. Bultink et al., “Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 2, pp. 389–390, 2010.
[28] S. Finzel, J. Rech, S. Schmidt et al., “Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion,” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1587–1593, 2011.
[29] W. Yao, Z. Cheng, A. Pham et al., “Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization,” Arthritis & Rheumatism, vol. 58, no. 11, pp. 3485–3497, 2008.
[30] K. R. R. Rengasamy, H. Khan, S. Gowrishankar et al., “The role of flavonoids in autoimmune diseases: therapeutic updates,” Pharmacology & Therapeutics, vol. 194, 2018.
[31] B. Sun Pan, Y. Y. Kuo, T. Y. Chen, and Y. C. Liu, “Anti-oxidative and anti-inflammatory activities of two different species of a Chinese herb I-Tiao-Gung,” Life Sciences, vol. 77, no. 22, pp. 2830–2839, 2005.
[32] J. S. Smolen and G. Steiner, “Therapeutic strategies for rheumatoid arthritis,” Nature Reviews Drug Discovery, vol. 2, no. 6, pp. 473–488, 2003.
[33] A. Sucur, Z. Jajic, M. Artukovic et al., “Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells,” Arthritis Research & Therapy, vol. 19, no. 1, p. 142, 2017.
[34] S. L. Gaffen, R. Jain, A. V. Garg, and D. J. Cua, “The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing,” Nature Reviews Immunology, vol. 14, no. 9, pp. 585–600, 2014.
[35] A. Saxena, S. Khorasviani, S. Noel, D. Mohan, T. Donner, and A. R. A. Hamad, “Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy,” Cytokine, vol. 74, no. 1, pp. 27–34, 2015.
[36] A. Finnegan, C. D. Kaplan, Y. Cao, H. Eibel, T. T. Glant, and J. Zhang, “Collagen-induced arthritis is exacerbated in IL-10-deficient mice,” Arthritis Research & Therapy, vol. 5, no. 1, pp. R18–R24, 2003.
[37] M. P. Vincenti and C. E. Brinkerhoff, “The potential of signal transduction inhibitors for the treatment of arthritis is it all just JNK?,” Journal of Clinical Investigation, vol. 108, no. 2, pp. 181–183, 2001.
[38] R. Ganesan, H. M. Doss, and M. Rasool, “Majoon ushba, a polyherbal compound, suppresses pro-inflammatory mediators and RANKL expression via modulating NFκB and MAPKs signaling pathways in fibroblast-like synoviocytes from adjuvant-induced arthritic rats,” Immunologic Research, vol. 64, no. 4, pp. 1071–1086, 2016.
[39] E. A. Ross, A. J. Naylor, J. D. O’Neil et al., “Treatment of inflammatory arthritis via targeting of tristetraprolin, a master
regulator of pro-inflammatory gene expression,” *Annals of the Rheumatic Diseases*, vol. 76, no. 3, pp. 612–619, 2016.

[40] Y. Yang, Y. Ye, Q. Qiu et al., “Triptolide inhibits the migration and invasion of rheumatoid fibroblast-like synoviocytes by blocking the activation of the JNK MAPK pathway,” *International Immunopharmacology*, vol. 41, pp. 8–16, 2016.

[41] Z. Han, D. L. Boyle, K. R. Aupperle, B. Bennett, A. M. Manning, and G. S. Firestein, “Jun N-terminal kinase in rheumatoid arthritis,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 291, no. 1, pp. 124–130, 1991.

[42] Z. Han, D. L. Boyle, L. Chang et al., “c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis,” *Journal of Clinical Investigation*, vol. 108, no. 1, pp. 73–81, 2001.

[43] M. Ohori, M. Takeuchi, R. Maruki, H. Nakajima, and H. Miyake, “FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice,” *Naunyn-Schmiedeberg’s Archives of Pharmacology*, vol. 374, no. 4, pp. 311–316, 2006.

[44] I. A. Schepetkin, L. N. Kirpotina, D. Hammaker et al., “Anti-inflammatory effects and joint protection in collagen-induced arthritis after treatment with IQ-1S, a selective c-Jun N-terminal kinase inhibitor,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 353, no. 3, pp. 505–516, 2015.

[45] T. Kallunki, T. Deng, M. Hibi, and M. Karin, “c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions,” *Cell*, vol. 87, no. 5, pp. 929–939, 1996.